-

Calyxo, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, announced today that Joe Catanese, Ph.D., Chief Executive Officer of Calyxo will present at the J.P. Morgan 44th Annual Healthcare Conference on Monday, January 12, 2026, at 8:30 AM PT in San Francisco, CA.

“Being invited to present at the J.P. Morgan Healthcare Conference for the first time is a meaningful milestone,” said Joe Catanese. “We’ve made significant progress expanding adoption of the CVAC System and advancing our clinical evidence"

Share

“Being invited to present at the J.P. Morgan Healthcare Conference for the first time is a meaningful milestone for Calyxo and reflects the strong momentum we’ve built across our business,” said Joe Catanese. “We’ve made significant progress expanding adoption of the CVAC System, advancing our clinical evidence, and scaling our commercial footprint. I look forward to sharing how our continued focus on innovation and clinical evidence is driving growth and improving care for patients with kidney stone disease.”

About Kidney Stones

According to the American Urological Association, approximately 10% of people in the U.S. will have a kidney stone at some point in their lives. Kidney stone disease is a painful condition that can result in significant healthcare costs (Current Urology Reports estimates $4.1 billion in annual direct treatment costs by 2030).

About the CVAC System

The CVAC System was FDA-cleared in 2024 and enables a minimally invasive approach for kidney stone clearance. It is an all-in-one solution designed to efficiently and effectively remove kidney stones. It uses irrigation and vacuum aspiration to continuously clear stone fragments during and after laser lithotripsy, enabling physicians to achieve a stone-free outcome.

About Calyxo, Inc.

Calyxo, Inc. is an innovation-driven medical device company focused on improving care for patients with kidney stones by delivering paradigm-shifting solutions that enable urologists to safely, effectively and efficiently achieve unrivaled clinical outcomes. Learn more at calyxoinc.com.

“CVAC” and “Calyxo” are registered trademarks of Calyxo, Inc.

Contacts

Media Contact:
Alyssa Paldo
Alyssa.paldo@finnpartners.com
M: +1 847 791 8085

Industry:

Calyxo, Inc.

Release Versions
English

Contacts

Media Contact:
Alyssa Paldo
Alyssa.paldo@finnpartners.com
M: +1 847 791 8085

More News From Calyxo, Inc.

Calyxo Expands Board of Directors as Number of Patients Treated with its CVAC® System Crosses 20,000 Milestone

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, marked key milestones as adoption of the steerable ureteroscopic renal evacuation (SURE) procedure using the company’s CVAC System continues to accelerate. The company has appointed Dana G. Mead, Jr. to its board of directors, and it has reached more than 20,000 patients treated to date with the CVAC System, further establishing the technology as a new standard...

Calyxo Debuts Reverse Deflection CVAC System and Reveals Groundbreaking Two-Year ASPIRE Data at WCET 2025, Underscoring the Technology’s Role in Advancing Endourology

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, today announced the launch of Reverse Deflection on its second-generation CVAC System—an enhancement that empowers endourologists to perform the SURE procedure using their preferred steering mode. Calyxo also shared that for the first time, 15 presentations demonstrating the safety, efficacy, and benefits of SURE using the CVAC System were featured at WCET 2025,...

Real-World Experience and Pre-Clinical Data Presented at the American Urological Association 2025 Meeting Shed Light on the Unique Advantages of the CVAC System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company advancing innovative solutions for kidney stone treatment, today announced the results of multiple real-world, clinical, and pre-clinical studies demonstrating the safety, efficacy, and clinical utility of the steerable ureteroscopic renal evacuation (SURE) procedure using the Company’s CVAC System. The data were presented at the American Urological Association (AUA) 2025 Annual Meeting, which took place April 26-29 in...
Back to Newsroom